BIOTECanada welcomes the announcement by CTI Life Sciences of its new $134 million fund. CTI’s new fund combined with Canadian funds created in late 2014 by Versant Ventures ($305 million) and Teralys Capital ($279 million) makes available nearly three quarters of a billion dollars in new investment capital for Canada’s biotech sector. Read more